EUVIMEDEUVIMED entdecken
Crossref

Real-world association between ivacaftor initiation and lung function variability: A registry study

Rhonda D Szczesniak, Eleni-Rosalina Andrinopoulou, Hancheng Li, Raksha Jain, Nicole Mayer-Hamblett, Josh Ostrenga, Anushka K Palipana, David J Pasta, Margaret Rosenfeld, Jonathan Todd, Elizabeth A Cromwell, Wayne J Morgan

Journal of Cystic Fibrosis · 2025

DOI: 10.1016/j.jcf.2025.01.014 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Cystic Fibrosis, 2025. Verfasst von Rhonda D Szczesniak und 11 weiteren Autor:innen. Beteiligte Einrichtung: Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA; University of Cincinnati, Cincinnati, OH, USA. Electronic address: Rhonda.Szczesn…. Hauptthemen laut MEDLINE: Cystic Fibrosis, Quinolones, Aminophenols, Chloride Channel Agonists. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 27 Literaturangaben. Gefördert von: Cystic Fibrosis Foundation, National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Increased variability in forced expiratory volume in 1 s of % predicted (FEV1pp) has been associated with accelerated lung function decline in individuals with cystic fibrosis (CF). Lung function variability is a leading predictor of decline, but the association between ivacaftor initiation and FEV1pp variability has not been characterized. METHODS: We utilized the Cystic Fibrosis Foundation Patient Registry (2008-2020) to quantify this association and identify risk factors of increased variability. Linear mixed effects models were used to compare pre- and post-ivacaftor initiation periods for established outcome measures of FEV1pp variability: i) maximum and ii) median deviations from the best (highest) FEV1pp during each period; iii) maximum, iv) median, and v) standard deviation about the trendline of the FEV1pp trajectory in each period. RESULTS: The analysis cohort included 527 individuals. Across outcomes, FEV1pp variability was reduced after ivacaftor initiation (median reduction: 1.85 % predicted). Reductions were robust with highest magnitudes of effect identified using maximum deviation from the best FEV1pp while most consistent findings were reached with trendline measures, particularly median deviation. Risk factors for increased FEV1pp variability differed between children and adults but were consistent between G551D and R117H subgroups. F508del homozygous patients followed contemporaneously exhibited minimal change in variability (median change: 0.25 % predicted). Reduced variability weakly correlated with changes in FEV1pp and slope, but higher levels of pre-ivacaftor variability were associated with greater reductions. CONCLUSIONS: There was evidence that ivacaftor initiation reduces FEV1pp variability in people with CF. Quantifying FEV1pp variability may have utility as a marker of therapeutic effectiveness.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cystic FibrosisQuinolonesAminophenolsChloride Channel AgonistsHumansRegistriesMaleFemaleForced Expiratory VolumeAdultChildRespiratory Function TestsAdolescentYoung AdultLung

Stichwörter der Autor:innen

Fev1Highly effective modulatorLongitudinalMutationPatient registryStability

Substanzen

QuinolonesivacaftorAminophenolsChloride Channel Agonists

Autor:innen und Institutionen

  • Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA; University of Cincinnati, Cincinnati, OH, USA. Electronic address: Rhonda.Szczesniak@cchmc.org.
  • Erasmus Medical Center, Rotterdam, The Netherlands.
  • Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA; University of Cincinnati, Cincinnati, OH, USA.
  • University of Texas Southwestern Medical Center, Dallas, TX, USA.
  • Seattle Children's Hospital, Seattle, WA, USA; University of Washington, Seattle, WA, USA.
  • Cystic Fibrosis Foundation, Bethesda, MD, USA.

Förderung

  • Cystic Fibrosis Foundation
  • National Institutes of Health

Zitieren

APA

Szczesniak, R. D., Andrinopoulou, E. R., Li, H., Jain, R., Mayer-Hamblett, N., Ostrenga, J., Palipana, A. K., Pasta, D. J., Rosenfeld, M., Todd, J., Cromwell, E. A., & Morgan, W. J. (2025). Real-world association between ivacaftor initiation and lung function variability: A registry study. Journal of Cystic Fibrosis. https://doi.org/10.1016/j.jcf.2025.01.014

Vancouver

Szczesniak RD, Andrinopoulou ER, Li H, Jain R, Mayer-Hamblett N, Ostrenga J, et al. Real-world association between ivacaftor initiation and lung function variability: A registry study. Journal of Cystic Fibrosis. 2025. doi:10.1016/j.jcf.2025.01.014

BibTeX
@article{Szczesniak2025,
  author = {Szczesniak, Rhonda D and Andrinopoulou, Eleni-Rosalina and Li, Hancheng and Jain, Raksha and Mayer-Hamblett, Nicole and Ostrenga, Josh and Palipana, Anushka K and Pasta, David J and Rosenfeld, Margaret and Todd, Jonathan and Cromwell, Elizabeth A and Morgan, Wayne J},
  title = {Real-world association between ivacaftor initiation and lung function variability: A registry study},
  journal = {Journal of Cystic Fibrosis},
  year = {2025},
  doi = {10.1016/j.jcf.2025.01.014}
}
Kostenlos starten →